<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519593</url>
  </required_header>
  <id_info>
    <org_study_id>MCCSPb-8-12-2020</org_study_id>
    <nct_id>NCT04519593</nct_id>
  </id_info>
  <brief_title>ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma</brief_title>
  <official_title>ABSOLUTELY: A Multicenter Randomized Controlled Trial of Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mother and Child Clinic Saint-Petersburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mother and Child Clinic Saint-Petersburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3 multicenter unblinded randomized controlled trial comparing the temporary uterine&#xD;
      blood supply occlusion with conventional approach during laparoscopic myomectomy in patients&#xD;
      with uterine leiomyoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoints&#xD;
&#xD;
      â€¢ Assess the volume of blood loss&#xD;
&#xD;
      Secondary endpoints&#xD;
&#xD;
        -  Compare the rates of intra- and postoperative complications, the necessity of blood&#xD;
           transfusion, length of surgery, length of hospital and ICU stay, and leiomyoma symptoms&#xD;
           relief&#xD;
&#xD;
        -  Determine the procedure impact on fertility by evaluating the level of anti-mullerian&#xD;
           hormone, pregnancy rates, pregnancy complications, and the way of delivery&#xD;
&#xD;
      Patients who meet study inclusion criteria will be randomized into one of two treatment arms:&#xD;
      1) laparoscopic myomectomy preceded by temporary uterine blood supply occlusion or 2)&#xD;
      laparoscopic myomectomy with a conventional approach.&#xD;
&#xD;
      Sixty patients will undergo laparoscopic myomectomy preceded by temporary uterine blood&#xD;
      supply occlusion performed by gynecologists at Mother and Child Clinic Saint-Petersburg and&#xD;
      other institutions participating in the study. Sixty patients will undergo conventional&#xD;
      laparoscopic myomectomy performed by gynecologists at Mother and Child Clinic&#xD;
      Saint-Petersburg and other institutions participating in the study.&#xD;
&#xD;
      Patients eligible for inclusion, after signing an informed voluntary consent to participate&#xD;
      in the study, will be randomized in a 1:1 ratio to the treatment groups using stratification&#xD;
      by age, size, and leiomyoma nodes location.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients who meet study inclusion criteria will be randomized into one of two treatment arms: 1) laparoscopic myomectomy preceded by temporary uterine blood supply occlusion or 2) laparoscopic myomectomy with a conventional approach.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>At the end of the intervention</time_frame>
    <description>Evaluation of blood loss volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment characteristics</measure>
    <time_frame>During 6 months since the intervention</time_frame>
    <description>Rates of intra- and postoperative complications, necessity of blood transfusion, length of surgery, length of hospital and ICU stay, leiomyoma symptoms relief</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on fertility</measure>
    <time_frame>During 18 months since the intervention</time_frame>
    <description>Level of anti-mullerian hormone, rate of pregnancy, pregnancy complications, the way of delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Uterine Leiomyoma</condition>
  <condition>Uterine Fibroid</condition>
  <condition>Leiomyoma, Uterine</condition>
  <condition>Myoma;Uterus</condition>
  <condition>Laparoscopic Myomectomy</condition>
  <condition>Postoperative Complications</condition>
  <condition>Blood Loss, Surgical</condition>
  <condition>Fertility Issues</condition>
  <condition>Pregnancy Complications</condition>
  <arm_group>
    <arm_group_label>Laparoscopic myomectomy with temporary blood supply occlusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic myomectomy is performed with prior visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional laparoscopic myomectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laparoscopic myomectomy is performed without prior temporary blood supply occlusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic myomectomy with prior temporary uterine blood supply occlusion</intervention_name>
    <description>Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.</description>
    <arm_group_label>Laparoscopic myomectomy with temporary blood supply occlusion</arm_group_label>
    <other_name>Temporary uterine arteries occlusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional laparoscopic myomectomy</intervention_name>
    <description>Laparoscopic myomectomy without prior temporary uterine blood supply occlusion</description>
    <arm_group_label>Conventional laparoscopic myomectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic uterine leiomyoma&#xD;
&#xD;
          -  Size of leiomyoma node &gt;5 cm based on imaging&#xD;
&#xD;
          -  Leiomyoma node types 3, 4, 5, 6 according to The International Federation of&#xD;
             Gynecology and Obstetrics (FIGO) classification or type 2 not feasible to be removed&#xD;
             during hysteroscopy&#xD;
&#xD;
          -  Single or multiple nodes&#xD;
&#xD;
          -  Absent contraindications for laparoscopic myomectomy&#xD;
&#xD;
          -  Voluntarily signed informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Asymptomatic uterine leiomyoma&#xD;
&#xD;
          -  Size of leiomyoma node &lt;5 cm based on imaging&#xD;
&#xD;
          -  Absence of leiomyoma node types 3, 4, 5, 6 according to FIGO classification and type 2&#xD;
             not feasible to be removed during hysteroscopy&#xD;
&#xD;
          -  Planned simultaneous hysteroscopy with leiomyoma node excision&#xD;
&#xD;
          -  Current pregnancy and breastfeeding&#xD;
&#xD;
          -  Suspicion of a malignant uterine tumor&#xD;
&#xD;
          -  Prior uterine leiomyoma surgery&#xD;
&#xD;
          -  Contraindications for laparoscopic myomectomy&#xD;
&#xD;
          -  Lack of decision-making capacity hindering signing the consent to participate in the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrei Dubinin, MD, PhD</last_name>
    <phone>+79811506112</phone>
    <email>andub@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pavel Sorokin, MD</last_name>
    <phone>+79835218691</phone>
    <email>sor-pavel@ya.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mother and Child Clinic Saint-Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei Dubinin, MD, PhD</last_name>
      <phone>+79811506112</phone>
      <email>andub@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Andrei Dubinin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavel Sorokin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mother and Child Clinic Saint-Petersburg</investigator_affiliation>
    <investigator_full_name>Andrey Dubinin, MD, PhD</investigator_full_name>
    <investigator_title>Gynecologist</investigator_title>
  </responsible_party>
  <keyword>temporary uterine artery occlusion</keyword>
  <keyword>temporary uterine blood supply occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

